Hematopoietic stem cell transplantation and immunotherapy for pediatric hematologic malignancies

Rahul Naithani, Daniel Ortiz, Andrea Marcela Webster-Carrion, Sunil Joshi, Asha B. Pillai

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hematopoietic stem cell transplantation (HSCT) can be curative for hematologic malignancies. As a result of receiving preparative treatments for HSCT (“conditioning”) involving high-dose chemotherapy with/without total body irradiation (TBI), patients become profoundly immunocompromised and prone to opportunistic infections while awaiting donor immune reconstitution. These infectious risks, coupled with other complications including graft rejection, graft-versus-host disease (GVHD), and disease relapse have been the main obstacles to HSCT success. Recent advances in transplant immunology, supportive care and management of complications, and reduced toxicity conditioning have made HSCT an increasingly efficacious curative modality. More recently, immunotherapy is extending the curative potential of harnessing the immune system against cancer, with the goal of reducing the toxicities normally associated with conventional HSCT.

Original languageEnglish (US)
Title of host publicationEncyclopedia of Tissue Engineering and Regenerative Medicine
PublisherElsevier
Pages65-79
Number of pages15
Volume1-3
ISBN (Electronic)9780128136997
ISBN (Print)9780128137000
DOIs
StatePublished - Jan 1 2019

Keywords

  • Allogeneic
  • Autologous
  • Bone marrow
  • Engraftment
  • Graft-versus-host disease
  • Hsc
  • Peripheral blood stem cell
  • Rejection
  • Relapse
  • Sinusoidal obstruction syndrome
  • Stem cell transplantation
  • Total body irradiation
  • Umbilical cord blood

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Hematopoietic stem cell transplantation and immunotherapy for pediatric hematologic malignancies'. Together they form a unique fingerprint.

Cite this